Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating incomes. Despite these mixed results, DexCom's revenue trajectory indicates ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales ...

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

NSYNC’s Lance Bass shares his journey with type 1.5 diabetes, also known as latent autoimmune diabetes in adults (LADA). The ...

Retirement Systems of Alabama lowered its holdings in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.5% in the 4th quarter, ...